• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 3. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977

Recent Advances in the Study of 873945-77-8 and 1-Propanol, 3-[(2-fluorophenyl)methoxy]-: A Comprehensive Research Brief

The chemical compound with the CAS number 873945-77-8 and the specific product name 1-Propanol, 3-[(2-fluorophenyl)methoxy]- has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique fluorophenyl methoxy group, has shown promising potential in various therapeutic applications. Recent studies have focused on elucidating its molecular mechanisms, pharmacokinetics, and potential as a lead compound in drug development. This research brief aims to synthesize the latest findings and provide a comprehensive overview of the current state of knowledge regarding this compound.

One of the key areas of investigation has been the compound's interaction with biological targets, particularly in the central nervous system (CNS). Preliminary studies suggest that 1-Propanol, 3-[(2-fluorophenyl)methoxy]- exhibits selective binding affinity to certain neurotransmitter receptors, which could explain its observed effects in preclinical models. Researchers have employed advanced techniques such as X-ray crystallography and molecular docking simulations to map the binding sites and understand the structural basis of its activity. These findings are crucial for the rational design of derivatives with improved efficacy and reduced side effects.

In addition to its CNS activity, recent research has explored the compound's potential in oncology. In vitro and in vivo studies have demonstrated that 873945-77-8 can inhibit the proliferation of specific cancer cell lines by modulating key signaling pathways. For instance, one study published in the Journal of Medicinal Chemistry reported that the compound induces apoptosis in breast cancer cells via the PI3K/AKT pathway. These findings highlight its potential as a novel chemotherapeutic agent, though further studies are needed to assess its safety and efficacy in clinical settings.

Another significant aspect of the research has been the optimization of the synthetic route for 1-Propanol, 3-[(2-fluorophenyl)methoxy]-. Recent advancements in organic synthesis have enabled more efficient and scalable production of this compound, which is critical for its further development. A study in Organic Process Research & Development detailed a novel catalytic method that reduces the number of steps and improves yield, making it more feasible for large-scale manufacturing. Such innovations are essential for transitioning from laboratory-scale research to industrial applications.

Despite these promising developments, challenges remain. The pharmacokinetic profile of 873945-77-8, including its absorption, distribution, metabolism, and excretion (ADME) properties, requires further characterization. Recent pharmacokinetic studies have revealed variability in bioavailability, which could impact its therapeutic utility. Researchers are now focusing on formulating the compound to enhance its stability and delivery, with some success in developing prodrug versions that improve oral absorption.

In conclusion, the compound 873945-77-8 and its derivative 1-Propanol, 3-[(2-fluorophenyl)methoxy]- represent a promising area of research in chemical biology and pharmaceuticals. Recent studies have shed light on its mechanisms of action, therapeutic potential, and synthetic optimization. However, further research is needed to address remaining challenges and fully realize its clinical potential. This brief underscores the importance of continued investigation and collaboration across disciplines to advance our understanding and application of this compound.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)